Cycle Pharmaceuticals secures $25m debt financing

This article was originally published here

This strategic financing allows Cycle to build on the success of NITYR (nitisinone) Tablets, which treats patients with the rare genetic metabolic disease, hereditary tyrosinemia type 1. Cycle’s

The post Cycle Pharmaceuticals secures $25m debt financing appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply